PRESTRELSKI STEVEN (Chief Scientific Officer) sold 2.4% of their position (10K shares) of XERIS PHARMACEUTICALS INC on the open market
Open‑market sale worth $60.1K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/15/2021ACC: 0001346302-21-000004
Officer· Chief Scientific Officer
Since Dec 2018
-10K
Net shares
Net seller
$60.1K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
10K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−10K
Price / share
$6.01
Trade value
$60.06K
% of position
2.4%
1/13/2021
416.82K→406.82K
Total
Net shares
−10K
Net value
-$60.06K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/13/2021 | S · Sale | −10K | $6.01 | $60.06K | 2.4% | 416.82K | 406.82K |
| Total | −10K | -$60.06K | ||||||
Derivative Transactions0
No derivative transactions reported